NEW YORK (GenomeWeb News) – Orchid Cellmark’s third-quarter revenues declined around 4 percent year over year due to lower service revenues in the UK.
The Princeton, NJ-based DNA testing services firm reported revenues of $14.9 million for the three-month period ended Sept. 30, compared with revenues of $15.6 million in the comparable period of 2007. A decline in UK revenues was partially offset by a 4 percent increase in US revenues during the quarter, the firm said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.